Neuroscience
An interesting piece on what's about to hit consumers: the marketing of Lunesta (eszopiclone):
You May Want to Sleep on It
Enter the Next 'Miracle' Drug: A Sleeping Pill You Can Take Long-Term. Ads for Lunesta Won't Likely Give That Theme a Rest. This Time Will Consumers Be More Leery?
By Sandra G. Boodman
Washington Post
Tuesday, January 18, 2005; Page HE01
Read the full article (free registration required)
- "sleeping Sickness” (human African Trypanosomiasis)
From yesterday's New York Times: Jump-Start on Slow Trek to Treatment for a Disease By DONALD G. McNEIL Jr. Published: January 8, 2008 Last month, the Bill and Melinda Gates Foundation donated $19 million to the Drugs for Neglected Diseases Initiative...
- Alzheimer's Dementia: "to Screen, Or Not To Screen"
A short piece in today's Washington Post about the potential problems and potential benefits of broad screenings for dementia of Alzheimer's disease in the general population of aging persons: To Screen, or Not to Screen Experts Debate Mass Testing...
- The Game Brain
From The Washington Post:Preventive Maintenance For the Brain Can Exercise or Mind Games Help? A Look at the Evidence By Alicia Ault Special to The Washington Post Tuesday, February 21, 2006; Page HE01 If it seems you're forgetting more as you grow...
- Business World: New Insomnia Meds, Including Takeda's Ramelteon (rozerem, Tak-375)
A brief overview to some of the anticipated insomnia medications trending from this year to next, this is from a recent Reuters report, as published on the International Herald Tribune website:New entries shake insomnia market's slumber Reuters ...
- Business World: Takeda's Ramelteon (tak-375)
A Reuters report:Takeda may extend sleeping pill's use for Alzheimer's Mon Jul 11, 2005 05:41 AM ET TOKYO, July 11 (Reuters) - Japan's biggest drug maker, Takeda Pharmaceutical Co. Ltd ... said on Monday it is on track to release a sleeping...
Neuroscience
Watch Out: Under-recognized, Under-treated Means Ad Blitz
An interesting piece on what's about to hit consumers: the marketing of Lunesta (eszopiclone):
You May Want to Sleep on It
Enter the Next 'Miracle' Drug: A Sleeping Pill You Can Take Long-Term. Ads for Lunesta Won't Likely Give That Theme a Rest. This Time Will Consumers Be More Leery?
By Sandra G. Boodman
Washington Post
Tuesday, January 18, 2005; Page HE01
Read the full article (free registration required)
- "sleeping Sickness” (human African Trypanosomiasis)
From yesterday's New York Times: Jump-Start on Slow Trek to Treatment for a Disease By DONALD G. McNEIL Jr. Published: January 8, 2008 Last month, the Bill and Melinda Gates Foundation donated $19 million to the Drugs for Neglected Diseases Initiative...
- Alzheimer's Dementia: "to Screen, Or Not To Screen"
A short piece in today's Washington Post about the potential problems and potential benefits of broad screenings for dementia of Alzheimer's disease in the general population of aging persons: To Screen, or Not to Screen Experts Debate Mass Testing...
- The Game Brain
From The Washington Post:Preventive Maintenance For the Brain Can Exercise or Mind Games Help? A Look at the Evidence By Alicia Ault Special to The Washington Post Tuesday, February 21, 2006; Page HE01 If it seems you're forgetting more as you grow...
- Business World: New Insomnia Meds, Including Takeda's Ramelteon (rozerem, Tak-375)
A brief overview to some of the anticipated insomnia medications trending from this year to next, this is from a recent Reuters report, as published on the International Herald Tribune website:New entries shake insomnia market's slumber Reuters ...
- Business World: Takeda's Ramelteon (tak-375)
A Reuters report:Takeda may extend sleeping pill's use for Alzheimer's Mon Jul 11, 2005 05:41 AM ET TOKYO, July 11 (Reuters) - Japan's biggest drug maker, Takeda Pharmaceutical Co. Ltd ... said on Monday it is on track to release a sleeping...